Wong and Wilson Tam and Xiang Qian Lao and Harry H
83-1
Objectives: Identify the FDA-approved indications and off-label uses for atenolol, including hypertension, angina, and acute myocardial infarction
The pooled hazard ratios (HRs) of acute myocardial infarction, stroke, hospitalization for heart failure, and most metabolic
1% vs
1% (metoprolol) died from any causes within 5 Metoprolol users were more likely to die from any causes and CVS diseases
Background: Existing trials almost exclusively used atenolol to represent the entire beta-blocker class
75, P<0
57, CI= 0
Although greater amounts of physical activity (PA) are associated with well-known reductions in cardiovascular and all-cause mortality, fewer than one-quarter of
The longitudinal associations of urinary concentrations of diphenyl phosphate (DPHP), bis(2-chloroethyl) phosphate (BCEP), and bis(1,3-dichloro-2-propyl) phosphate (BDCPP) with
8 RCTs met the selection criteria
For CARE participants, we also considered several secondary outcomes, including death due to coronary disease, the development of symptomatic heart failure, fatal or nonfatal myocardial infarction confirmed by serum creatine kinase Mortality, all-cause hospitalization, and quality of life outcomes were narratively synthesized
85)
Only 1 trial (n = 232) compared atenolol to carvedilol in patients with AMI
25)
9% vs 55 Characteristics of each study and associated clinical outcomes were extracted, including all-cause mortality, coronary heart disease, stroke, and cardiovascular death
Atenolol has been described as providing a “pseudo antihypertensive effect” because it lowers peripheral arterial pressure but not central aortic pressure and therefore may not reduce the pressure to which
22 A meta-analysis of trials with atenolol in patients with hypertension revealed that there were no discernible differences between atenolol or placebo in the reduction of all-cause mortality (1
the amlodipine-based arm had lower rates of all cause mortality (hazard ratio [HR] 0
Atenolol is used to treat high blood pressure The negative association between masked tachycardia and an increased risk for major CV events and all-cause mortality was documented in a study of 7602 patients with newly diagnosed hypertension who were followed there was a significantly higher mortality, CV mortality and risk of stroke with atenolol treatment than with other active Mortality from all causes was 63 and 104 in losartan and atenolol groups, respectively; 0
Interpretation: Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH
The dialytic clearances of atenolol, metoprolol, and bisoprolol were all significantly higher than carvedilol’s clearance of 24±18 ml/min (P<0
When evaluated for a decrease in risk of stroke, metoprolol proved to be superior to atenolol as well
Atenolol therapy was associated with significantly lower all-cause (12%) and cardiovascular mortality (32%) than was metoprolol tartrate, which the authors attributed to better adherence and blood There was no difference in all‐cause mortality between beta‐blockers and placebo (RR 0
00 to 1
Many conditions related to mortality can be avoided or delayed, or the risk reduced through healthy lifestyle choices
In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model In addition to either losartan or atenolol, patients were treated with hydrochlorothiazide and other antihypertensive medications as needed to obtain a blood pressure goal of less than 140/90 mm Hg